Genpharmasec Limited , a prominent player in the pharmaceutical and laboratory testing sectors, has announced its unaudited financial results for the first quarter, ending June 30. The company has demonstrated robust growth across key financial metrics on both standalone and consolidated bases.

Standalone Performance

On a standalone basis, Genpharmasec Limited reported impressive growth in its revenue from operations. The company's revenue surged to Rs 1,211.32 lakh, marking a significant increase of 128% compared to Rs 530.29 lakh in the same quarter of the previous year.

The company's profitability also saw substantial improvement. Profit for the period rose to Rs 155.92 lakh, up from Rs 58.87 lakh, representing a remarkable growth of 165%.

Consolidated Results

Genpharmasec's consolidated performance mirrored its standalone success. The consolidated revenue from operations reached Rs 1,204.32 lakh, compared to Rs 519.50 lakh in the previous year's quarter, showcasing a strong growth of 132%.

Consolidated profit for the period stood at Rs 121.52 lakh, a significant increase from Rs 28.68 lakh, reflecting a growth of 324%.

Segment-wise Performance

The company operates primarily in two segments: pharmaceuticals and laboratory testing. The pharmaceutical segment continued to be the major revenue driver, contributing Rs 1,167.09 lakh to the consolidated revenue. The laboratory testing segment, operated through its subsidiary Clinigenome India Private Limited, generated revenue of Rs 37.24 lakh.

Financial Highlights

Other Key Developments

The company's Board of Directors, in a meeting held on August 7, reviewed and approved these unaudited financial results. The meeting commenced at 2:00 p.m. and concluded at 2:50 p.m.

Genpharmasec Limited also reported that there has been no deviation in the use of proceeds from its rights issue, as confirmed in its statement to the BSE Limited.

Conclusion

Genpharmasec Limited's quarterly results demonstrate the company's ability to achieve significant growth in both revenue and profitability. The substantial year-over-year increases in key financial metrics reflect the company's strong market position and operational efficiency in the pharmaceutical and laboratory testing sectors.

Genpharmasec Limited has successfully completed the acquisition of a 70% stake in Derren Healthcare Private Limited (DHPL) for INR 34.15 crores, as announced in a regulatory filing on July 25, 2025. This strategic move marks a significant expansion for Genpharmasec into the pharmaceutical formulations manufacturing sector.

Acquisition Details

The acquisition, which was finalized on July 25, 2025, follows agreements signed in September 2023. With this transaction, Derren Healthcare has become a subsidiary of Genpharmasec Limited, in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

About Derren Healthcare

Derren Healthcare Private Limited, incorporated on October 8, 2018, is a research-oriented company specializing in the development of high-quality pharmaceutical products. The company focuses on both generic and innovative finished formulations, while also providing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services.

Financial Performance

Derren Healthcare has demonstrated impressive growth over the past three financial years:

This rapid growth trajectory underscores the potential value of the acquisition for Genpharmasec Limited.

Strategic Implications

The acquisition allows Genpharmasec to expand its activities and make a foray into formulation manufacturing. This move is expected to enhance Genpharmasec's capabilities in the pharmaceutical sector and potentially drive future growth.

Transaction Details

The acquisition was completed through a cash consideration, with the payment made through the banking system. Genpharmasec acquired 70% of the equity shares in Derren Healthcare, which has an authorized share capital of INR 7.50 crores and a paid-up share capital of approximately INR 7.40 crores.

Mr. Sohan Chaturvedi, Whole Time Director & CFO of Genpharmasec Limited, confirmed the completion of the acquisition in the regulatory filing.

This strategic move by Genpharmasec Limited represents a significant step in its growth strategy, potentially positioning the company for expanded operations in the pharmaceutical formulations market.